Product Description
Serlopitant, an oral, once-daily neurokinin 1 receptor antagonist, for treatment of psoriatic pruritus in a phase 2, randomized clinical trial (NCT03343639).
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vyne Therapeutics
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Psoriasis|Dermatitis, Atopic|Prurigo|Pruritus|Neurodermatitis
Phase 2: Alcoholism|Pruritus|Overactive Bladder|Neurodermatitis|Urinary Incontinence|Prurigo|Psoriasis|Dermatitis, Atopic|Refractory Chronic Cough|Unexplained Chronic Cough|Epidermolysis Bullosa|Burns Unspecified
Phase 1: Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-173742 |
JapicCTI-173742 | P1 |
Completed |
Kidney Diseases |
None |
|||
NCT03836001 |
NCT03836001 | P2 |
Completed |
Epidermolysis Bullosa|Pruritus |
2021-12-06 |
2022-12-24 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03841331 |
MTI-117 | P2 |
Completed |
Pruritus |
2019-12-10 |
55% |
2021-05-20 |
Primary Endpoints |
NCT03343639 |
MTI-109 | P2 |
Completed |
Psoriasis|Pruritus |
2018-10-23 |
62% |
2021-05-20 |
Primary Endpoints|Treatments |
2017-003250-16 |
2017-003250-16 | P2 |
Completed |
Unexplained Chronic Cough|Refractory Chronic Cough |
2018-09-06 |
20% |
2022-03-13 |
Treatments |
NCT03282591 |
MTI-110 | P2 |
Completed |
Refractory Chronic Cough|Unexplained Chronic Cough |
2018-08-15 |
20% |
2021-05-20 |
Primary Endpoints|Treatments |
NCT02654483 |
NCT02654483 | P2 |
Completed |
Pruritus|Epidermolysis Bullosa |
2018-06-28 |
34% |
2021-05-20 |
Primary Endpoints |
NCT02975206 |
ATOMIK | P2 |
Completed |
Dermatitis, Atopic|Pruritus |
2018-01-16 |
60% |
2021-05-20 |
Primary Endpoints|Treatments |
NCT02975271 |
AUBURN | P2 |
Terminated |
Burns Unspecified|Pruritus |
2017-01-17 |
2025-08-27 |
Primary Endpoints|Treatments |
|
2013-005024-42 |
Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo Nodularis | P2 |
Completed |
Pruritus |
2016-06-08 |
2022-03-13 |
Treatments |
|
NCT02196324 |
TCP-102 | P2 |
Completed |
Prurigo|Neurodermatitis |
2016-05-27 |
2021-05-20 |
Primary Endpoints|Treatments |
|
NCT01951274 |
TCP 101 | P2 |
Completed |
Pruritus |
2014-12-02 |
2022-05-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
2014-001581-10 |
Study of the Neurokinin-1 Receptor Antagonist VDP-737 in Subjects with Chronic Pruritus | P2 |
Completed |
Pruritus |
2014-12-02 |
2022-03-13 |
Treatments |
|
NCT00835718 |
MK0594-020 | P2 |
Terminated |
Alcoholism |
2010-03-11 |
2021-05-20 |
Primary Endpoints|Treatments |
|
2008-004686-26 |
2008-004686-26 | P2 |
Completed |
Alcoholism |
2010-03-11 |
2022-03-12 |
Treatments |
|
2005-005606-23 |
MK-0594 Overactive Bladder Dose-Ranging Study | P2 |
Terminated |
Overactive Bladder |
2007-09-24 |
2022-03-12 |
Treatments |
|
2005-006201-12 |
ND | P2 |
Terminated |
Overactive Bladder |
2007-09-24 |
2022-03-12 |
Treatments |
|
NCT00290563 |
MK0594-003 | P2 |
Completed |
Urinary Incontinence|Overactive Bladder |
2007-08-01 |
2021-05-20 |
Primary Endpoints|Treatments |
|
JapicCTI-173781 |
JapicCTI-173781 | P2 |
Terminated |
Pruritus |
None |
|||
NCT03540160 |
Itch | P3 |
Terminated |
Psoriasis|Prurigo|Pruritus|Dermatitis, Atopic |
2020-04-08 |
16% |
2021-05-20 |
Primary Endpoints|Treatments |
2017-004210-25 |
2017-004210-25 | P3 |
Completed |
Pruritus|Prurigo |
2020-02-06 |
8% |
2022-03-13 |
Treatments |
NCT03546816 |
MTI-105 | P3 |
Completed |
Pruritus|Prurigo|Neurodermatitis |
2020-01-14 |
15% |
2021-05-20 |
Primary Endpoints|Treatments |
NCT03677401 |
MTI-106 | P3 |
Completed |
Prurigo|Neurodermatitis|Pruritus |
2020-01-09 |
8% |
2021-05-20 |
Primary Endpoints |
2017-004211-40 |
2017-004211-40 | P3 |
Terminated |
Dermatitis, Atopic|Pruritus|Prurigo|Psoriasis |
2019-08-07 |
16% |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/08/2021 |
News Article |
Allergy Treatment Market Global Industry Trends, Share, Size and Forecast Report |
|
10/25/2021 |
News Article |
Allergy Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) |
|
08/23/2021 |
News Article |
Allergy Treatment Market Size, Demand, Outlook, Trends, Revenue, Future Growth Opportunities |
|
02/10/2021 |
News Article |
World Psoriasis Pipeline Insight Report 2021 - ResearchAndMarkets.com |
|
01/01/2021 |
PubMed |
Benefits and harms of NK1 R antagonists in pruritus: A systematic review and meta-analysis. |
|
12/01/2020 |
PubMed |
Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial. |
|
04/01/2020 |
PubMed |
Prurigo nodularis: New treatments on the horizon. |